NOXXON's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

10-Apr-2012 - Germany

Noxxon Pharma announced that a preclinical study of the SDF-1 inhibiting Spiegelmer NOX-A12 significantly delayed post-irradiation glioblastoma recurrence. The data from this study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.

The study, conducted in collaboration with the Stanford University School of Medicine, investigated the efficacy of NOX-A12 on brain tumor recurrences following irradiation in an animal model. In this model rats begin to die of brain tumors from approximately 120 days of age. These rats were treated with a single dose of whole brain irradiation (20 Gy) which was immediately followed by two different doses of NOX-A12 injected subcutaneously for either 4 or 8 weeks. Neither radiation nor NOX-A12 alone significantly affected the lifespan of the tumor-bearing rats; however the combination of the NOX-A12 (high or low dose) for 8 weeks and irradiation resulted in a significantly prolonged lifespan with the higher dose increasing median lifespan from 189 days for controls to 349 days (P value <0.0001)

NOX-A12 doses and treatment times in this preclinical study were chosen based on equivalents found to be safe and well tolerated in humans. Based on the results obtained from this study, the researchers believe that a clinical trial of NOX-A12 in combination with standard therapy in first-line glioblastoma patients would be justified at this point.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances